Everest Medicines (HKEX 1952.HK, a China-based biopharmaceutical company, announced on Sunday that it has named Rogers Yongqing Luo as its new chief executive officer effective immediately.

Luo will also hold the position of executive director on the company's board of directors.

Luo has over 25 years of experience in the healthcare industry. He has held the position of president and general manager, Greater China at Brii Biosciences, CEO of TSB Therapeutics Global, vice president and China general manager at Gilead Sciences. He handled sales, marketing, government affairs and market access functions for various multinational pharmaceutical companies including Roche and Novartis, and served Novartis headquarter in Switzerland.